| Fiscal Period | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
| Issuance( Retirement)of Debt Net | -18.73 | -18.13 | -16.87 | -15.62 |
| Net Changein Cash | 474.68 | 29.23 | -251.25 | -119.00 |
| Cash Taxes Paid | 81.71 | 254.23 | 264.71 | 120.51 |
| Net Income/ Starting Line | 1,255.19 | 959.80 | 837.37 | 767.47 |
| Total Cash Dividends Paid | -749.38 | -541.57 | -1,525.50 | -506.64 |
| Changesin Working Capital | 103.12 | -193.20 | -310.45 | -0.64 |
| Cashfrom Operating Activities | 1,289.90 | 582.02 | 484.23 | 810.75 |
| Cash Interest Paid | 1.31 | 1.80 | 1.40 | 1.99 |
| Cashfrom Financing Activities | -769.42 | -561.50 | -1,543.32 | -524.24 |
| Depreciation/ Depletion | 66.79 | 69.68 | 65.77 | 68.19 |
| Other Investing Cash Flow Items Total | -21.08 | 39.93 | 851.89 | -370.87 |
| Capital Expenditures | -24.72 | -31.22 | -44.04 | -34.64 |
| period Type | - | - | - | - |
| Non- Cash Items | -135.20 | -254.26 | -108.46 | -24.27 |
| Financing Cash Flow Items | -1.31 | -1.80 | -0.96 | -1.99 |
| period Length | 12.00 | 12.00 | 12.00 | 12.00 |
| Cashfrom Investing Activities | -45.80 | 8.71 | 807.85 | -405.51 |
GlaxoSmithKline Pharmaceuticals Dividend GlaxoSmithKline Pharmaceuticals Bonus GlaxoSmithKline Pharmaceuticals News GlaxoSmithKline Pharmaceuticals AGM GlaxoSmithKline Pharmaceuticals Rights GlaxoSmithKline Pharmaceuticals Splits GlaxoSmithKline Pharmaceuticals Board Meetings GlaxoSmithKline Pharmaceuticals Key Metrics GlaxoSmithKline Pharmaceuticals Shareholdings GlaxoSmithKline Pharmaceuticals Profit Loss GlaxoSmithKline Pharmaceuticals Balance Sheet GlaxoSmithKline Pharmaceuticals Q1 Results GlaxoSmithKline Pharmaceuticals Q2 Results GlaxoSmithKline Pharmaceuticals Q3 Results GlaxoSmithKline Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks